BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Shehab M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Mohammad H, Cherian P, Al-Khairi I, Alphonse Thanaraj T, Channanath A, Ali H, Abu-Farha M, Abubaker J, Al-Mulla F. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. Vaccines (Basel) 2021;9:1471. [PMID: 34960217 DOI: 10.3390/vaccines9121471] [Reference Citation Analysis]
2 Magalhães T, Granado MC, Manuel AR, Espinheira MDC, Trindade E. Impact of COVID-19 in Pediatric Patients and Young Adults with Inflammatory Bowel Disease. GE Port J Gastroenterol. [DOI: 10.1159/000522073] [Reference Citation Analysis]
3 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shehab M, Zurba Y, Al Abdulsalam A, Alfadhli A, Elouali S. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study. Vaccines (Basel) 2021;10:55. [PMID: 35062716 DOI: 10.3390/vaccines10010055] [Reference Citation Analysis]